Fig. 3: The CPT score correlates with increased neoantigen burden in MIBC. | British Journal of Cancer

Fig. 3: The CPT score correlates with increased neoantigen burden in MIBC.

From: Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients

Fig. 3

a Patterns of mutational signatures and total number of neoantigens in patient subgroups defined by CPT score in TCGA cohort. Kruskal–Wallis test was performed (*P < 0.05; **P < 0.01, ***P < 0.001). b The pathway scores of antigen processing and presentation were compared among patient subgroups defined by CPT score. Kruskal–Wallis test was performed (***P < 0.001). c Higher CPT score is associated with increased T cell receptor repertoire richness and clonotype diversity. Kruskal–Wallis test was performed (***P < 0.001). d The pathway scores of T cell receptor signalling were compared among patient subgroups defined by CPT score. Kruskal–Wallis test was performed (***P < 0.001). HRD homologous recombination deficiency, MMR mismatch repair, SNV single-nucleotide variant, TCR T cell antigen receptor.

Back to article page